摘要
目的研究亚甲基四氢叶酸还原酶(MTHFR)C667T基因多态性对汉族肥胖患者高尿酸血症(HUA)发生风险的影响。方法选取2017年1月至2019年8月保定市第一中心医院收治的136例HUA患者(HUA组)及体检中心150例健康人群(对照组)作为研究对象,比较两组一般资料、MTHFR C667T基因型频率及等位基因频率分布,以logistic多元回归方程分析影响HUA发生的因素,通过分层分析、相对超危险度比(RERI)、归因比(AP)、交互作用指数(S)评价肥胖与MTHFRC677T基因多态性对HUA的交互作用。结果HUA组BMI、收缩压、高脂血症患者占比较对照组高(P<0.05);HUA组TT基因型频率、T等位基因频率均较对照组高(P<0.05);高BMI、高收缩压、高脂血症、TT基因型、T等位基因是HUA发生的危险因素(P<0.05);HUA组BMI≥28 kg/m2患者占比高于对照组(P<0.05);BMI≥28 kg/m2时,TT型基因在组间分布比较,差异具有统计学意义(P<0.05);交互作用分析显示,RERI=3.040,AP=0.406,S=4.464。结论MTHFR C667T基因TT型纯合子突变携带增加HUA的风险,MTHFR C667T基因多态性、肥胖在HUA的发生中存在正向交互作用。
Objective To study the effect of methylenetetrahydrofolate reductase(MTHFR)C667T gene polymorphism on the risk of hyperuricemia(HUA)in Han obese patients.Methods A total of 136 HUA patients(the HUA group)and 150 normal subjects(the control group)from January 2017 to August 2019 in the hospital were enrolled.The general data,MTHFR C667T genotype frequency and allele frequency were compared between the two groups.Logistic multiple regression equation was used to analyze the factors affecting HUA.The interaction between obesity and polymorphism of MTHFRC677T gene on HUA was evaluated by stratified analysis,relative risk ratio(RERI),attribution ratio(AP)and interaction index(S).Interaction with HUA.Results The BMI,systolic blood pressure and hyperlipidemia patients in the HUA group were higher than the control group(P<0.05).The TT genotype frequency and T allele frequency in the HUA group were higher than those in the control group(P<0.05).High BMI,high systolic blood pressure,hyperlipidemia,genotype TT,allele T were risk factors associated with HUA(P<0.05).BMI≥28 kg/m2,the difference of TT genotype distribution between the group of comparison is statistically significant(P<0.05).The interaction analysis showed that RERI=3.040,AP=0.406,S=4.464.Conclusion The TT homozygous mutation of MTHFR C667T gene carries the risk of increasing HUA.There is a positive interaction between MTHFR C667T gene polymorphism and obesity in the occurrence of HUA.
作者
夏丽芳
何倩
王鑫
宋茜茜
张月娥
李志红
XIA Lifang;HE Qian;WANG Xin;SONG Qianqian;ZHANG Yue′e;LI Zhihong(the Second Department of Endocrinology,Baoding First Central Hospital,Baoding,Hebei 017000,China;the Third Department of Internal Medicine,Lixian Hospital,Hebei 071400,China;Department of Endocrinology,Baoding First Central Hospital,Baoding,Hebei 017000,China;the Second Department of Rehabilitation,Baoding First Central Hospital,Baoding,Hebei 017000,China)
出处
《重庆医学》
CAS
2021年第1期58-62,共5页
Chongqing medicine
基金
河北省卫生和计划生育委员会专项课题(8776869)。
